Floatz logo

Dostarlimab

Pancreas Neoplasms

Hopital Fochmonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

381 Active assets in the Pancreas Neoplasms cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →